問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Cardinal Tien Hospital (在職)

Division of General Internal Medicine

Division of Endocrinology

Taipei Tzu Chi Hospital (在職)

Division of Endocrinology

Fu Jen Catholic University Hospital (在職)

Division of Endocrinology

Division of Endocrinology

Hualien Tzu Chi Hospital

更新時間：2023-09-19

裴馰
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

裴馰

List

63Cases

2012-11-12 - 2018-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate Cardiovascular Outcomes of TAK-875, 50 mg in Addition to Standard of Care in Subjects with Type 2 Diabetes and with Cardiovascular Disease or Multiple Risk Factors for Cardiovascular Events

  • Condition/Disease

    Type 2 Diabete

  • Test Drug

    TAK-875

Participate Sites
7Sites

Terminated7Sites

2007-09-01 - 2009-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2013-01-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-03-01 - 2015-07-31

Phase III

A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    MK-3102

Participate Sites
16Sites

Terminated16Sites

2013-11-13 - 2019-12-27

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-04-22 - 2017-10-04

Phase III

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY

  • Condition/Disease

    TYPE 2 DIABETES

  • Test Drug

    Ertugliflozin (MK-8835/PF-04971729)

Participate Sites
11Sites

Terminated11Sites

2021-01-22 - 2023-03-23

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting2Sites

Recruiting8Sites

2010-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-08-01 - 2014-01-31

Phase III

LY2189265 compares with insulin Glargine and the combined use of insulin Lispro on the treatment to target of type 2 diabetes (AWARD-4: Evaluation of the weekly use of LY2189265 in patients with type 2 diabetes. 4 [Assessment of Weekly AdministRation of LY2189265 in Diabetes-4]

  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    LY2189265

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2009-07-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB